Prospective COVID-19 post-Immunization Serological Cohort in Munich - Determination of immune response in vaccinated subjects

Prospective COVID-19 post-Immunization Serological Cohort in Munich - Determination of immune response in vaccinated subjects - KoCo-Impf

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00030407

Enrollment

8000

Registered

2022-10-17

Start date

2021-06-16

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 SARS-CoV-2

Interventions

Group 1: Health Care Workers and residents of Munich were informed about the study in health care facilities and via the website of the Institute of Infectious Diseases and Tropical Medicine and invit

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Adult (over 18 years) individuals from the Munich municipality and from counties (Landkreise) in the vicinity of Munich who received their first COVID-19 vaccination and – after thorough information and consideration - explicitly consent to the study procedures.

Exclusion criteria

Exclusion criteria: Diseases and conditions that impede an informant consent, insufficient command of the German language to a degree that impedes informed consent.

Design outcomes

Primary

Measure	Time frame
Seroprevalence and -incidence of SARS-CoV-2 antibodies in Health Care Workers in the Munich population	—

Secondary

Measure	Time frame
Baseline visit: - Determining the baseline immune status of people who are receiving Covid-19-vaccines in Munich and the prevalence of individuals (silently and symptomatic) infected before vaccination. Follow-up visits: - Describe and compare the dynamics of antibody titers of vaccinated individuals over time and in relation to the vaccine they received or preexisting immunity. - Determine the relative risk of post-immunization infection with COVID-19 (variants) in relation to the antibody titer at the time of infection. In the case of post-immunization infections, the affected individuals should be recruited by other studies which analyse breakthrough infections more specifically. - Collect through a short, structured questionnaire data on COVID-infection-19 status, vaccine status, factors that may influence immune response (e.g. immune suppression) and basic demographic data that allow a matching of population demographics with data of the KoCo19 study.	—

Measure

Time frame

Baseline visit: - Determining the baseline immune status of people who are receiving Covid-19-vaccines in Munich and the prevalence of individuals (silently and symptomatic) infected before vaccination. Follow-up visits: - Describe and compare the dynamics of antibody titers of vaccinated individuals over time and in relation to the vaccine they received or preexisting immunity. - Determine the relative risk of post-immunization infection with COVID-19 (variants) in relation to the antibody titer at the time of infection. In the case of post-immunization infections, the affected individuals should be recruited by other studies which analyse breakthrough infections more specifically. - Collect through a short, structured questionnaire data on COVID-infection-19 status, vaccine status, factors that may influence immune response (e.g. immune suppression) and basic demographic data that allow a matching of population demographics with data of the KoCo19 study.

—

Countries

Germany

Contacts

Public ContactChristian Janke

Institut für Infektions- und Tropenmedizin, LMU Klinikum, LMU München

Christian.Janke@lrz.uni-muenchen.de+49 (0)89 4400-59870

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026